Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,322
datasets available to search
ShareScore release 0.9.0
Dataset results
2,322 results for “Circulation”
Circulating Tumor DNA Sequencing Provides Comprehensive Mutation Profiling for Pediatric Central Nervous System Tumors
Tumor molecular profiling is increasingly important for the diagnosis and clinical management of childhood brain tumors, including diffuse midline glioma (DMG). We established a targeted deep sequencing approach using the TruSight Oncology 500 ctDNA exome panel to detect tumor genomic mutations and copy number variations in circulating tumor DNA from children diagnosed with DMG. In this study, we present the sensitivity, specificity, and clinical implications of our liquid biopsy sequencing approach for tumor genome profiling in children with DMG.
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma
In this study, we show that the plasma representation of mutations exceeds the bulk tumor representation in most cases, making classic Hodgkin Lymphoma (cHL) particularly amenable to noninvasive profiling. Leveraging single-cell transcriptional profiles of cHL tumors, we demonstrate hazard ratios (HRs) circulating tumor DNA (ctDNA) shedding to be shaped by DNASE1L3, whose increased tumor microenvironment-derived expression drives high ctDNA concentrations. Using this insight, we comprehensively profile 366 patients, revealing two distinct cHL genomic subtypes with characteristic clinical and prognostic correlates, as well as distinct transcriptional and immunological profiles. Furthermore, we identify a novel class of truncating IL4R-mutations that are dependent on IL13 signaling and therapeutically targetable with IL4R blocking antibodies. Finally, we demonstrate the clinical value of pre- and on-treatment ctDNA levels for longitudinally refining cHL risk prediction, and for detection of radiographically occult minimal residual disease. Collectively, these results support the utility of noninvasive strategies for genotyping and dynamic monitoring of cHL as well as capturing molecularly distinct subtypes with diagnostic, prognostic, and therapeutic potential. All patients were treated at cancer centers across Europe and North America between 2011 and 2020. The following 3 cancer centers--Stanford, CA, USA; Bellinzona, Switzerland; and Leuven, Belgium--were included.
Global gene expression profiling of circulating endothelial cells in SARS-CoV-2-infected cynomolgus macaques
GEO Series GSE287567. Macaca fascicularis. 6 samples. Type: Expression profiling by high throughput sequencing.
Plasma circulating extracellular RNAs in left ventricular remodeling post-myocardial infarction
GEO Series GSE112690. Homo sapiens. 331 samples. Type: Expression profiling by RT-PCR.
Dataset related to article "Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer."
<p>PURPOSE:</p> <p>To evaluate the clinical-pathological and prognostic significance of the circulating PD-L1 level in patients with surgically treated NSCLC, by combining data for PD-L1 expression with other immune-related markers and tumor metabolism.</p> <p>METHODS:</p> <p>Overall, 40 patients with resected NSCLC (stage Ia-IIIa) who had preoperative blood storage and underwent staging PET/CT were enrolled for the study. In all cases, we determined plasma levels of PD-L1 (pg/ml), immune-reactive areas (IRA %) covered by CD3, CD68, CD20, CD8, PD-1, and PD-L1 in the tumor specimen, and metabolic parameters on PET, i.e., SUV<sub>max</sub>, SUV<sub>peak</sub>, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Variables were statistically analyzed to establish their association with disease-free survival (DFS).</p> <p>RESULTS:</p> <p>The circulating levels of PD-L1 in the bloodstream could be determined in 38/40 (95%) samples. The mean and median expression levels were 34.86 pg/ml and 24.83 pg/ml, respectively. We did not find any statistically significant correlation between circulating PD-L1 and tissue expression of PD-L1/PD-1. Some mild degree of positive correlation was determined between tissue PD-L1 and SUV<sub>max</sub> (ρ =&thinsp;0.390; p =&thinsp;0.0148). Hierarchical clustering combining circulating, tissue, and metabolic parameters identified clusters with high metabolic tumor burden or high expression of plasma PD-L1 levels (Z score ≥ 2) as having a poor DFS (p =&thinsp;0.033). The multivariate analysis detected stage and metabolism (i.e., SUV<sub>max</sub> and SUV<sub>peak</sub>) as independent prognostic factors for DFS.</p> <p>CONCLUSION:</p> <p>Plasma levels of PD-L1 are independent of the expression of PD-1/PD-L1 in NSCLC tumor tissue and, when combined with other clinical-pathological parameters, allow for the identification of clusters with different outcomes.</p>
Effects of Horizontal Resolution on Long-Range Equatorward Radiation of Near-inertial Internal Waves in Ocean General Circulation Models
<p>Effects of Horizontal Resolution on Long-Range Equatorward Radiation of Near-inertial Internal Waves in Ocean General Circulation Models</p> <p> </p> <p>All Figure Data</p>
Dataset for optimization results of circulating cooling water system for codensning power plant
Open the record for dataset details and reuse information.
Dataset related to article "Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer"
<p>This record contains raw data related to article<strong> "</strong>Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer<strong>".</strong></p> <p>We have previously demonstrated that longitudinal untargeted analysis of plasma samples withdrawn from patients with high-grade serous ovarian cancer (HGS-EOC) can intercept the presence of molecular recurrence (TRm) earlier than the diagnosis of clinical recurrence (TRc). This finding opens a clinical important temporal window to acquire through plasma sample analysis a real-time picture of those emerging molecular lesions that will drive and sustain the growth of relapsed disease and ultimately will confer resistance. In this proof of principle study, the same genomic libraries obtained at the diagnosis (T0), TRm and TRc were further analyzed by targeted resequencing approach to sequence the coding region of a panel of 65 genes to provide longitudinal analysis of clonal evolution as a novel strategy to support clinical decisions for the second-line treatment. Experiments were performed on plasma and tumor tissues withdrawn on a selection of previously analyzed cohorts of cases (i.e., 33 matched primary and synchronous lesions and 43 plasma samples from 18 patients). At T0, the median concordance of mutations shared by each tumor tissue biopsy and its matched plasma sample was 2.27%. This finding confirms the limit of a single tumor biopsy to be representative of the entire disease, while plasma analysis can recapitulate most of the main molecular lesions of the disease. A comparable scenario was observed during longitudinal analysis, where, with the exception of the <em>TP53</em> gene and germline mutations in <em>BRCA1/2</em> genes, no other gene shared the same locus specific gene mutation across T0, TRm and TRc time points. This high level of temporal heterogeneity has important implications for planning second-line treatment. For example, in three out of 13 cases, plasma ctDNA analysis at TRm or TRc reported acquired novel variants in the <em>TP53BP1</em> gene not present at T0. In particular, patient 21564, potentially eligible for PARP-inhibitor (PARPi) treatment at the time of diagnosis (<em>BRCA1</em> c.5182delA mutation), would unlikely respond to these drugs in second-line therapy due to the presence of eight distinct <em>TP53BP1</em> variants in plasma samples collected TRc. This study demonstrates that liquid biopsy provides a real-time molecular picture to intercept those actionable genetic vulnerabilities or drug resistance mechanisms that could be used to plan a more rational second-line treatment.</p>
Dataset for "How Do Tropical Precipitation and Circulations Respond to the Cloud-Radiative Effect Changes?"
<p>More information is available from the data manager upon request.</p>
Data used in JGR-A paper "Observational relationship between the Convective Aggregation, Sea Surface Temperature, and Large-scale circulation"
<p>Data used in the JGR-A paper "Observational relationship between the Convective Aggregation, Sea Surface Temperature, and Large-scale circulation" by Shuhei Matsugishi and Masaki Satoh </p>
: Dataset related to the article "Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study"
<p>This record contains raw data related to the article “Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study”.</p> <p><em><strong>Abstract</strong></em></p> <p><strong>Background: </strong>Advanced glycation end-products (AGEs) and their interaction with the receptor for advanced glycation end-products (RAGE) play a pivotal role in the development and progression of type 2 diabetes. In this retrospective cohort study, we explored the association of circulating levels of soluble RAGE (sRAGE) isoforms, i.e., endogenous secretory esRAGE and cleaved cRAGE, AGEs and their respective ratios with 15-year all-cause mortality in type 2 diabetes. <strong>Methods: </strong>Baseline AGEs and sRAGE isoforms concentration were measured by ELISA in 362 patients with type 2 diabetes and in 125 age- and gender-matched healthy control subjects (CTR). Independent predictors of mortality were determined using Cox proportional-hazards models and used to build and validate a nomogram for all-cause mortality prediction in type 2 diabetes. <strong>Results: </strong>AGEs, total sRAGE, cRAGE and the AGEs/sRAGE and AGEs/esRAGE ratios were significantly increased in patients with type 2 diabetes compared to CTR (p < 0.001). In CTR subjects, but not in type 2 diabetes patients, a significant negative correlation between cRAGE and age was confirmed (p = 0.003), whereas the AGEs/sRAGE (p = 0.032) and AGEs/cRAGE (p = 0.006) ratios were positively associated with age. At an average follow-up of 15 years (4,982 person-years), 130 deaths were observed. The increase in the AGEs/cRAGE ratio was accompanied by a higher risk of all-cause mortality in patients with type 2 diabetes (HR per each SD increment = 1.30, 95% CI 1.15-1.47; p < 0.001). Moreover, sRAGE was associated with the development of major adverse cardiovascular events (MACE) in type 2 diabetes patients without previous MACE (OR for each SD increase: 1.48, 95% CI 1.11-1.89). A nomogram based on age, sex, HbA1c, systolic blood pressure, and the AGEs/cRAGE ratio was built to predict 5-, 10- and 15-year survival in type 2 diabetes. Patients were categorized into quartiles of the monogram scores and Kaplan-Meier survival curves confirmed the prognostic accuracy of the model (log-rank p = 6.5 × 10<sup>- 13</sup>). <strong>Conclusions: </strong>The ratio between AGEs and the cRAGE isoform is predictive of 15-year survival in patients with type 2 diabetes. Our data support the assessment of circulating AGEs and soluble RAGE isoforms in patients with type 2 diabetes as predictors of MACE and all-cause mortality.</p> Enable Ginger<em>Cannot connect to Ginger</em> Check your internet connection<br> or reload the browserDisable in this text fieldRephraseRephrase current sentence<span class="ginger-floatingG-bar-tool-mistakes-count">26</span>Log in to edit with Ginger×
Codes for A hidden connection of meso-scale convective rainfall and large-scale circulations over the eastern Pacific
<h4><strong>README</strong></h4><h4><strong>System requirments</strong></h4><ul><li><strong>Figure 1, ED_Figure_1, and ED_FIGURE_3</strong>: IDL (v8.5) on Linux OS</li><li><strong>Figure 3, Figure 4, ED_Figure_4, and ED_FIGURE_5</strong>: Python (v3.7.3) on Linux OS</li><li><strong>Figure 2 and ED_Figure_2</strong>: Sigmaplot (v10.0)</li></ul><h4><strong>Installation guide</strong></h4><p>The modules needed to run are in each directory. Each code requires execution time of less than 1 minute.</p><h4><strong>Demo</strong></h4><p>Sample data, code, and expected output are located in their repective directories.</p><h4><strong>Instruction for use</strong></h4><p>IDL code) type <i>idl</i> to enter IDL mode</p><p>idl> .r (figure name).pro </p><p>Python code) </p><p>> python (figurename).py</p>
Plasma Circulating Deoxyribonucelic Acid (DNA) as a Response Marker
ClinicalTrials.gov study NCT00318604. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Circulating miRNA signature in bile of pateints with primary sclerosing cholangitis (PSC) vs cholangiocarcinoma (CC)
GEO Series GSE72593. Homo sapiens. 5 samples. Type: Expression profiling by RT-PCR.
Changes in miRNA expression in circulating whole blood resutling from exposure to neurotoxic doses of D-amphetamine
GEO Series GSE115835. Rattus norvegicus. 14 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Circulating miRNAs detect high versus low visceral adipose tissue inflammation in patients living with obesity
GEO Series GSE240273. Homo sapiens. 35 samples. Type: Expression profiling by high throughput sequencing.
Statistical algorithm enabled high precision tumor biomarker discovery for circulating extracellular vesicle-based cancer liquid biopsy
GEO Series GSE246925. Homo sapiens. 28 samples. Type: Expression profiling by high throughput sequencing.
Circulating microRNA and 5’ tRNA halves signatures of genotype-by-age interactions in the longlived Ames dwarf mouse.
GEO Series GSE69274. Mus musculus. 20 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Detection of hypermethylated circulating serum DNA in metastatic breast cancer and confirmation by the cMethDNA assay
GEO Series GSE52621. Homo sapiens. 36 samples. Type: Methylation profiling by array.
De novo sequencing of circulating microRNAs in locally advanced breast cancer
GEO Series GSE49035. Homo sapiens. 42 samples. Type: Non-coding RNA profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.